Chiome Bioscience Selects ProBioGen for Antibody Manufacturing Program
Nov 01 2017 Read 296 Times
ProBioGen AG, a service and technology provider for complex therapeutic glycoproteins and Chiome Bioscience Inc, a Japanese antibody discovery and development company, have jointly announced signing a service and license agreement. Under the agreement ProBioGen will apply its enhanced cancer cell-killing technology GlymaxX® to LIV-1205, a clinical candidate in an antibody manufacturing program for Chiome.
Specifically, ProBioGen will develop a stable GlymaxX® cell line, followed by process development and GMP manufacturing of the ADCC-enhanced cancer stem cell antibody, which will be optimised for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) cancer cell-killing activity.
Dr Koji Nakamura, Head of Drug Discovery Laboratories and former CEO of LivTech explained: “We have tested ProBioGen’s GlymaxX® technology for our antibody before and saw in-vivo in animal models an obviously potentiated cancer cell-killing efficacy of its afucosylated version. This, together with our long-standing relationship with the ProBioGen team, the company’s demonstrated track record in developing stable cell lines up to reliable GMP manufacturing for small and big biotechs, and the favourable, royalty-free commercial GlymaxX® Terms, made our selection quite simple.”
ProBioGen’s CEO Wieland Wolf, commented: “We look much forward to a productive partnership which combines Chiome’s outstanding antibody drug candidate, LIV-1205, with our own antibody development expertise and our GlymaxX ADCC enhancement technology to make together with Chiome a marked contribution to combat various cancers.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Why Does Nanotechnology Require Mass Spectrometry Spotlight Features Luminescence, UV & Microplate Readers - New Confocal Laser Scanning Microscope Combine...
View all digital editions
Jul 29 2018 Chicago, IL, USA
Jul 29 2018 Washington DC, USA
Aug 05 2018 Baltimore, MD, USA
Aug 06 2018 Westminster, CO, USA
Aug 06 2018 Berlin, Germany